PharmEnable
PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases
May 22, 2023 04:00 ET | PharmEnable
$7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group. Existing investors Cambridge Enterprise, University of Cambridge Enterprise Fund...
MateonLogo.jpg
MATEON PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS
November 16, 2020 06:55 ET | Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today announced financial results for the third quarter ended September...
MateonLogo.jpg
Mateon Therapeutics Closes $2.0 Million Financing
July 27, 2020 07:00 ET | Mateon Therapeutics, Inc.
AGOURA HILLS, California, July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of...
logo long.jpg
Global Metabolism Drugs Market to Surpass US$ 9.9 Billion by 2026 – Coherent Market Insights
July 16, 2018 10:00 ET | Coherent Market Insights
Seattle, July 16, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global metabolism drugs market was valued at US$ 5,765.3 million in 2017 and is projected to exhibit a CAGR of...